Medtecs International Announces Court-Ordered Dissolution of Resilient Medical; Liquidation Process Officially Concluded

Key Points for Investors

• Resilient Medical Dissolved by Singapore High Court: Following a hearing on 3 February 2026, the High Court of Singapore has granted an order for the dissolution of Resilient Medical, a subsidiary of Medtecs International Corporation Limited. The dissolution is effective as of 3 February 2026.
• Liquidation Process Completed: The court order and confirmation from the appointed liquidator mark the formal conclusion of the liquidation process for Resilient Medical. All necessary steps in the liquidation have been completed.
• No Further Actions Required: Medtecs International has confirmed that no further action is required from the company regarding the liquidation, and shareholders should not expect further monthly updates on this matter under Catalist Rule 704(22).
• No Material Financial Impact: Based on information available to the Board, the dissolution of Resilient Medical is not expected to have a material impact on the net tangible assets per share or the earnings per share of Medtecs International for the financial year ending 31 December 2026.

Important Information for Shareholders

• Potential Price Sensitivity: While the conclusion of the Resilient Medical liquidation does not have a material financial impact at this time, the winding-up and dissolution of a subsidiary can sometimes influence investor sentiment and trading volatility, especially if there are broader concerns about the group’s operations or strategic direction.
• Caution in Trading: The Board has advised all shareholders and potential investors to exercise caution in dealing with the Company’s securities. Investors should not take any action that may be prejudicial to their interests based solely on this announcement.
• Professional Advice Encouraged: Shareholders and potential investors who are uncertain about their investment decisions are encouraged to consult with professional advisers such as stockbrokers, bank managers, or solicitors.

Additional Details

• The announcement was issued by Clement Yang Ker-Cheng, Chairman and Executive Director of Medtecs International, on 11 February 2026.
• The company’s sponsor, PrimePartners Corporate Finance Pte. Ltd., has reviewed the announcement but the Singapore Exchange Securities Trading Limited (SGX-ST) does not assume responsibility for its contents.

Conclusion

The official dissolution of Resilient Medical signals the end of a drawn-out process that has involved multiple updates to shareholders over the past year. With the liquidation process now fully completed and no material financial impact expected, Medtecs International can now refocus on its core operations without the distraction of ongoing litigation or liquidation proceedings relating to Resilient Medical.

Investors are urged to monitor future company disclosures for any updates on operational performance, strategic initiatives, or other corporate events that may impact share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to consult their professional advisers before making any investment decisions. The Singapore Exchange Securities Trading Limited has not reviewed nor endorsed the contents of this article.

View Medtecs Intl Historical chart here